Sun Pharma has been granted exclusive rights to market Winlevi acne cream in the United States and Canada

Sun Pharma and Cassiopea SpA, a speciality pharma company, announced the completion of their exclusive licence and supply agreements for Winlevi cream, which is used to treat acne vulgaris in patients aged 12 and up.

According to a joint statement, the agreements will take effect on August 31, 2021.

Sun Pharma now has the exclusive right to commercialise Winlevi in the US and Canada. Cassiopea will be the exclusive supplier of the product, which is expected to be available in the US in the fourth quarter of 2021, it added.

Sun Pharma, North America CEO Abhay Gandhi said the expiration of the applicable waiting period under the US Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) clears the path for making Winlevi available to patients and healthcare providers in the US and Canada.

“With Winlevi, a unique product with a new mechanism of action for the topical treatment of acne vulgaris, we have further expanded our basket of innovative products to serve patients better,” he added.

The US Food and Drug Administration (USFDA) approved Winlevi (clascoterone cream 1 percent) in August 2020 for the topical treatment of acne vulgaris in patients 12 years and older, the statement said.

“We are very pleased that Winlevi will soon be widely available to dermatology healthcare providers and their patients in the US and Canada, benefiting from Sun Pharma’s strong established dermatology presence,” Cassiopea SpA CEO Diana Harbort said.

This transaction now allows Cassiopea to focus on its innovative dermatology pipeline, she added.

“We are very pleased that Winlevi will soon be widely available to dermatology healthcare providers and their patients in the US and Canada, benefiting from Sun Pharma’s strong established dermatology presence,” Cassiopea SpA CEO Diana Harbort said.

This transaction now allows Cassiopea to focus on its innovative dermatology pipeline, she added.

Shares of Sun Pharmaceutical Industries were trading at Rs 793.50 per scrip on BSE, up 0.88 percent from its previous close.

Medically Speaking

Share
Published by
Medically Speaking

Recent Posts

The Hidden Costs of Excessive Screen Time: How It Impacts Your Child’s Behavior and What You Can Do About It

Explore the profound effects of excessive screen time on your child’s behavior and development. Discover…

6 hours ago

Transform Your Heart Health: Simple Everyday Diet and Lifestyle Changes for a Happier, Stronger Heart

Discover how simple daily changes in your diet and lifestyle can significantly improve your heart…

6 hours ago

“Unraveling the Truth: Do Brain Tumours Only Affect Older Adults? Debunking Myths and Shedding Light on a Complex Condition”

This article explores the common misconception that brain tumours primarily affect older adults, revealing the…

6 hours ago

“Revolutionary Breakthrough: First-Ever Ovarian Cancer Vaccine Set to Transform Women’s Health and Combat a Silent Killer”

The first-ever ovarian cancer vaccine is poised to change the landscape of women's health by…

6 hours ago

“Battling the Monsoon Surge: Essential Strategies to Prevent Dengue and Chikungunya Infections in Delhi”

As dengue and chikungunya cases rise in Delhi during the monsoon season, understanding prevention strategies…

7 hours ago

NATURAL vs CHEMICAL SKINCARE: THE ESSENTIAL GUIDE TO CHOOSING WHAT’S BEST FOR YOUR SKIN

Skincare is a significant concern for women (and increasingly, men), with the quest for perfect,…

7 hours ago